Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Core Viewpoint - Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding Letter of Intent to evaluate a potential acquisition of Sciometrix Inc., which would lead to Tevogen holding a majority voting interest in Sciometrix if completed [1][2]. Group 1: Potential Transaction - The transaction aims to enhance Tevogen's capabilities and transition it into a revenue-generating healthcare enterprise by integrating Sciometrix's digital care management platform, Clinicus, and remote patient monitoring technologies with Tevogen.AI [2][11]. - Sciometrix has achieved significant milestones, becoming one of the top 25 digital healthcare companies in the USA, and aims to break into the top 10 with the addition of Tevogen.AI's capabilities [2]. - The proposed transaction is subject to due diligence, negotiation, execution of definitive documentation, required approvals, and customary closing conditions [2]. Group 2: Company Profiles - Tevogen is focused on creating a socially integrated healthcare enterprise that emphasizes affordability, efficiency, and scientific rigor, leveraging AI and precision T cell therapy platforms [4]. - Sciometrix provides enterprise care management, digital patient engagement, predictive analytics, and value-based care solutions to healthcare organizations across the nation [8]. Group 3: Strategic Initiatives - Tevogen is exploring additional strategic initiatives in life sciences, including domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers [3][7]. - The integration of Clinicus is expected to accelerate Tevogen's commercialization readiness by aligning clinical development with real-world patient engagement and outcomes tracking [11].